See more : Far East Bio-Tec Co., Ltd. (6886.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Essex Bio-Technology Limited (1061.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Essex Bio-Technology Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Shui On Land Limited (0272.HK) Income Statement Analysis – Financial Results
- InFinT Acquisition Corporation (IFIN) Income Statement Analysis – Financial Results
- Sinyi Realty Inc. (9940.TW) Income Statement Analysis – Financial Results
- Guangdong Guangzhou Daily Media Co., Ltd. (002181.SZ) Income Statement Analysis – Financial Results
- DIC India Limited (DICIND.NS) Income Statement Analysis – Financial Results
Essex Bio-Technology Limited (1061.HK)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.essexbio.com
About Essex Bio-Technology Limited
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.71B | 1.32B | 1.64B | 978.11M | 1.28B | 1.18B | 899.59M | 775.66M | 654.01M | 518.30M | 347.05M | 267.26M | 212.72M | 146.28M | 116.69M | 214.07M | 152.67M | 82.79M | 49.20M | 38.91M | 37.59M | 35.68M | 29.73M | 22.39M |
| Cost of Revenue | 167.26M | 128.38M | 241.89M | 184.28M | 246.12M | 202.92M | 161.99M | 152.64M | 124.42M | 107.04M | 36.11M | 23.56M | 20.28M | 11.94M | 11.04M | 111.48M | 82.84M | 34.13M | 7.53M | 4.40M | 18.00M | 11.48M | 5.99M | 3.82M |
| Gross Profit | 1.54B | 1.19B | 1.40B | 793.83M | 1.03B | 973.54M | 737.60M | 623.03M | 529.59M | 411.26M | 310.93M | 243.69M | 192.44M | 134.35M | 105.65M | 102.59M | 69.84M | 48.66M | 41.66M | 34.51M | 19.58M | 24.19M | 23.74M | 18.57M |
| Gross Profit Ratio | 90.20% | 90.26% | 85.23% | 81.16% | 80.76% | 82.75% | 81.99% | 80.32% | 80.98% | 79.35% | 89.59% | 91.18% | 90.47% | 91.84% | 90.54% | 47.93% | 45.74% | 58.77% | 84.68% | 88.69% | 52.10% | 67.81% | 79.86% | 82.94% |
| Research & Development | 39.14M | 23.51M | 23.52M | 8.58M | 3.41M | 18.12M | 6.43M | 5.65M | 10.78M | 7.03M | 6.56M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 216.97M | 155.98M | 153.76M | 111.61M | 81.72M | 68.91M | 40.41M | 47.96M | 51.16M | 42.37M | 25.57M | 26.75M | 19.88M | 11.93M | 15.30M | 16.30M | 61.85M | 45.60M | 37.24M | 10.39M | 40.31M | 11.15M | 7.56M | 4.46M |
| Selling & Marketing | 1.01B | 758.21M | 835.95M | 476.63M | 632.82M | 649.72M | 515.30M | 410.54M | 352.11M | 271.37M | 212.00M | 168.01M | 133.55M | 89.75M | 69.62M | 63.87M | 0.00 | 0.00 | 0.00 | 23.31M | 0.00 | 19.47M | 14.85M | 13.56M |
| SG&A | 1.19B | 914.19M | 989.71M | 588.24M | 714.54M | 718.63M | 555.70M | 458.50M | 403.27M | 313.73M | 237.58M | 194.77M | 153.44M | 101.68M | 84.92M | 80.17M | 61.85M | 45.60M | 37.24M | 33.71M | 40.31M | 30.62M | 22.41M | 18.01M |
| Other Expenses | 0.00 | -6.32M | -6.82M | -14.57M | -10.21M | -5.23M | 10.91M | 78.93K | 124.19K | 21.42K | 33.59K | 130.00 | 1.13M | 1.47M | 833.57K | -9.37M | -5.35M | 262.64K | 46.30K | -6.81M | -868.58K | -1.60M | -1.04M | -1.03M |
| Operating Expenses | 1.23B | 907.87M | 982.89M | 573.67M | 704.34M | 713.40M | 548.91M | 457.55M | 397.29M | 311.92M | 236.08M | 193.77M | 153.44M | 103.15M | 84.92M | 70.80M | 56.50M | 45.86M | 37.29M | 26.89M | 39.45M | 29.02M | 21.37M | 16.98M |
| Cost & Expenses | 1.40B | 1.04B | 1.22B | 757.95M | 950.46M | 916.31M | 710.89M | 610.18M | 521.71M | 418.97M | 272.19M | 217.33M | 173.72M | 115.08M | 95.96M | 182.28M | 139.34M | 79.99M | 44.82M | 31.29M | 57.45M | 40.50M | 27.36M | 20.80M |
| Interest Income | 12.34M | 8.88M | 9.86M | 7.58M | 3.60M | 3.33M | 6.62M | 3.45M | 278.49K | 206.28K | 219.00K | 1.42M | 1.46M | 0.00 | 0.00 | 355.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.21M | 11.47M | 9.22M | 1.42M | 6.96M | 7.40M | 9.50M | 9.69M | 2.06M | 3.81M | 2.05M | 1.70M | 0.00 | 0.00 | 4.37M | 7.71M | 1.21M | 0.00 | 0.00 | 0.00 | 297.82K | 61.90K | 0.00 | 0.00 |
| Depreciation & Amortization | 59.51M | 41.53M | 32.57M | 27.23M | 27.42M | 19.41M | 17.77M | 12.77M | 10.21M | 10.03M | 2.62M | 1.27M | 1.20M | 1.97M | 3.21M | 3.72M | 3.32M | 2.66M | 1.36M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 418.38M | 313.54M | 436.65M | 279.50M | 386.15M | 299.87M | 217.36M | 177.47M | 142.92M | 109.42M | 77.73M | 52.63M | 41.33M | 33.17M | 24.57M | 35.51M | 16.66M | 5.45M | 5.74M | 7.61M | -19.86M | -4.83M | 2.37M | 1.59M |
| EBITDA Ratio | 24.52% | 24.28% | 28.61% | 27.09% | 29.01% | 24.20% | 24.92% | 23.46% | 21.85% | 21.14% | 22.40% | 19.69% | 18.90% | 22.67% | 20.52% | 16.59% | 10.91% | 6.59% | 11.67% | 19.57% | -52.85% | -13.54% | 7.97% | 7.09% |
| Operating Income | 310.33M | 278.05M | 435.58M | 237.40M | 343.35M | 265.00M | 206.55M | 171.92M | 132.71M | 99.56M | 75.11M | 51.35M | 39.00M | 31.20M | 20.73M | 31.79M | 13.34M | 2.80M | 4.37M | 7.61M | -19.86M | -4.83M | 2.37M | 1.59M |
| Operating Income Ratio | 18.18% | 21.10% | 26.60% | 24.27% | 26.83% | 22.53% | 22.96% | 22.16% | 20.29% | 19.21% | 21.64% | 19.21% | 18.33% | 21.33% | 17.77% | 14.85% | 8.74% | 3.38% | 8.89% | 19.57% | -52.85% | -13.54% | 7.97% | 7.09% |
| Total Other Income/Expenses | 35.68M | 26.82M | 17.06M | 13.46M | 8.42M | 12.91M | 21.58M | -3.24M | 16.39M | -1.77M | -295.04K | -271.29K | 1.13M | -1.50M | 833.57K | -2.57M | -1.21M | -262.64K | 11.17M | -7.85K | -297.82K | -61.90K | -41.24K | -84.93K |
| Income Before Tax | 346.01M | 260.34M | 394.46M | 250.85M | 351.77M | 273.05M | 197.05M | 162.24M | 130.65M | 95.75M | 73.06M | 49.65M | 40.13M | 31.20M | 21.56M | 29.22M | 12.12M | 4.54M | 15.55M | 7.60M | -20.16M | -4.89M | 2.33M | 1.50M |
| Income Before Tax Ratio | 20.28% | 19.76% | 24.09% | 25.65% | 27.49% | 23.21% | 21.90% | 20.92% | 19.98% | 18.47% | 21.05% | 18.58% | 18.86% | 21.33% | 18.48% | 13.65% | 7.94% | 5.49% | 31.60% | 19.55% | -53.64% | -13.71% | 7.83% | 6.71% |
| Income Tax Expense | 70.75M | 34.93M | 48.49M | 31.93M | 49.26M | 41.96M | 29.75M | 25.95M | 25.76M | 20.48M | 18.17M | 10.66M | 6.92M | 4.61M | 4.81M | 2.26M | 1.12M | 781.69K | -11.17M | 7.85K | 297.82K | -1.07M | 364.76K | 614.73K |
| Net Income | 275.26M | 225.41M | 345.97M | 218.93M | 302.50M | 231.09M | 167.30M | 136.28M | 104.90M | 75.27M | 54.90M | 39.00M | 33.20M | 26.58M | 11.55M | 21.83M | 11.00M | 3.76M | 15.55M | 7.60M | -20.16M | -3.76M | 2.00M | 973.69K |
| Net Income Ratio | 16.13% | 17.11% | 21.13% | 22.38% | 23.64% | 19.64% | 18.60% | 17.57% | 16.04% | 14.52% | 15.82% | 14.59% | 15.61% | 18.17% | 9.90% | 10.20% | 7.21% | 4.55% | 31.60% | 19.55% | -53.64% | -10.55% | 6.74% | 4.35% |
| EPS | 0.49 | 0.39 | 0.60 | 0.38 | 0.52 | 0.39 | 0.30 | 0.24 | 0.19 | 0.14 | 0.10 | 0.07 | 0.06 | 0.05 | 0.02 | 0.04 | 0.02 | 0.01 | 0.03 | 0.01 | -0.04 | -0.01 | 0.01 | 0.00 |
| EPS Diluted | 0.47 | 0.38 | 0.58 | 0.37 | 0.51 | 0.38 | 0.29 | 0.24 | 0.19 | 0.13 | 0.10 | 0.07 | 0.06 | 0.05 | 0.02 | 0.04 | 0.02 | 0.01 | 0.03 | 0.01 | -0.04 | -0.01 | 0.01 | 0.00 |
| Weighted Avg Shares Out | 570.22M | 573.96M | 576.58M | 577.87M | 578.56M | 585.97M | 562.32M | 560.11M | 559.54M | 556.75M | 556.75M | 556.75M | 556.75M | 556.75M | 556.75M | 556.75M | 556.75M | 556.04M | 554.93M | 555.08M | 554.53M | 553.51M | 487.88M | 389.48M |
| Weighted Avg Shares Out (Dil) | 595.65M | 599.39M | 602.01M | 603.29M | 604.04M | 601.36M | 569.93M | 567.10M | 566.71M | 558.97M | 556.75M | 556.75M | 556.75M | 556.75M | 556.75M | 556.75M | 556.75M | 556.04M | 556.93M | 555.08M | 554.53M | 553.51M | 507.01M | 389.48M |
Source: https://incomestatements.info
Category: Stock Reports